WO1999004810A3 - Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment - Google Patents

Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment Download PDF

Info

Publication number
WO1999004810A3
WO1999004810A3 PCT/EP1998/004621 EP9804621W WO9904810A3 WO 1999004810 A3 WO1999004810 A3 WO 1999004810A3 EP 9804621 W EP9804621 W EP 9804621W WO 9904810 A3 WO9904810 A3 WO 9904810A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc class
lag
adjuvant
vaccination
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/004621
Other languages
French (fr)
Other versions
WO1999004810A2 (en
Inventor
Frederique Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Applied Research Systems ARS Holding NV
Original Assignee
Institut Gustave Roussy (IGR)
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020007000265A priority Critical patent/KR100603075B1/en
Priority to EP98945090A priority patent/EP1002108B1/en
Priority to DE69834330T priority patent/DE69834330T2/en
Priority to IL13421298A priority patent/IL134212A0/en
Priority to HK01100662.6A priority patent/HK1030014B/en
Priority to CA2293805A priority patent/CA2293805C/en
Priority to JP2000503862A priority patent/JP4723722B2/en
Priority to UA2000020976A priority patent/UA75322C2/en
Priority to EA200000161A priority patent/EA003740B1/en
Priority to BR9811037-3A priority patent/BR9811037A/en
Priority to AU92547/98A priority patent/AU753738B2/en
Priority to EEP200000039A priority patent/EE200000039A/en
Application filed by Institut Gustave Roussy (IGR), Applied Research Systems ARS Holding NV filed Critical Institut Gustave Roussy (IGR)
Publication of WO1999004810A2 publication Critical patent/WO1999004810A2/en
Publication of WO1999004810A3 publication Critical patent/WO1999004810A3/en
Priority to IL134212A priority patent/IL134212A/en
Priority to NO20000378A priority patent/NO20000378D0/en
Anticipated expiration legal-status Critical
Priority to US09/492,113 priority patent/US6410509B1/en
Priority to US10/041,600 priority patent/US7109026B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.
PCT/EP1998/004621 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment Ceased WO1999004810A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU92547/98A AU753738B2 (en) 1997-07-25 1998-07-23 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
DE69834330T DE69834330T2 (en) 1997-07-25 1998-07-23 USE OF MHC CLASS II LIGANDS AS ADJUVANTIES FOR VACCINATION AND LAG-3 FOR CANCER THERAPY
IL13421298A IL134212A0 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
HK01100662.6A HK1030014B (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
CA2293805A CA2293805C (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
JP2000503862A JP4723722B2 (en) 1997-07-25 1998-07-23 Use of MHC class II ligands as vaccine adjuvants and use of LAG-3 in cancer therapy
UA2000020976A UA75322C2 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy
EA200000161A EA003740B1 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligand, as a lag-3 or derivative, mutant form or soluble fragment lag-3, for preparation of immunotherapeutic medicament
BR9811037-3A BR9811037A (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as an adjuvant for vaccination and lag-3 in cancer treatment
KR1020007000265A KR100603075B1 (en) 1997-07-25 1998-07-23 Use of antigens for immunization of MHC class Ⅱ ligands and utilization of LAG-3 for cancer treatment
EP98945090A EP1002108B1 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
EEP200000039A EE200000039A (en) 1997-07-25 1998-07-23 Use of MHC Class II Ligand, Pharmaceutical Composition, Transfected Tumor Cells, Method of Preparing Transfected Cells and Tumor Cells, and Their Use
IL134212A IL134212A (en) 1997-07-25 2000-01-24 Use of lag-3 as an mhc class ii ligand in combination with an antigen for the manufacture of a medicament for amplifying a cell response to an antigen
NO20000378A NO20000378D0 (en) 1997-07-25 2000-01-25 Use of MHC class II ligands as adjuvants for vaccination and LAG-3 in cancer treatment
US09/492,113 US6410509B1 (en) 1997-07-25 2000-01-27 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
US10/041,600 US7109026B2 (en) 1997-07-25 2002-01-10 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401800.4 1997-07-25
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/492,113 Continuation US6410509B1 (en) 1997-07-25 2000-01-27 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

Publications (2)

Publication Number Publication Date
WO1999004810A2 WO1999004810A2 (en) 1999-02-04
WO1999004810A3 true WO1999004810A3 (en) 1999-07-08

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004621 Ceased WO1999004810A2 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment

Country Status (19)

Country Link
US (2) US6410509B1 (en)
EP (3) EP0893507A1 (en)
JP (1) JP4723722B2 (en)
KR (1) KR100603075B1 (en)
CN (1) CN1184320C (en)
AT (2) ATE478956T1 (en)
AU (1) AU753738B2 (en)
BR (1) BR9811037A (en)
CA (2) CA2293805C (en)
DE (2) DE69834330T2 (en)
DK (1) DK1002108T3 (en)
EA (3) EA200300092A1 (en)
EE (1) EE200000039A (en)
ES (1) ES2262242T3 (en)
IL (2) IL134212A0 (en)
NO (1) NO20000378D0 (en)
PT (1) PT1002108E (en)
UA (1) UA75322C2 (en)
WO (1) WO1999004810A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
FI1897548T4 (en) 2003-02-28 2024-09-03 The Johns Hopkins University T cell regulation
KR20050082389A (en) * 2004-02-18 2005-08-23 메덱스젠 주식회사 Pharmaceutical composition for treatment of transplantation rejection comprising concatameric immunoadhesin
FR2868781B1 (en) 2004-04-13 2008-02-22 Immutep VACCINE COMPOSITION COMPRISING ANTIGEN-COUPLED CLAY II MHC LIGAND, METHOD OF PREPARATION AND USES
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (en) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease
CN103270048B (en) 2010-11-10 2016-11-23 热体实验室有限公司 Novel adjuvant
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
CN103751778B (en) * 2014-01-28 2016-09-28 复旦大学 Cordycepin application in the immunological adjuvant preparing broad-spectrum vaccine potentiation
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
RU2684911C2 (en) 2014-10-07 2019-04-16 Ситлимик Инк. Peptid, obtained from hsp70, a pharmaceutical composition for the treatment or prevention of cancer, containing such peptid, immune response inductor and method for obtaining antigen-presenting path
WO2016094639A1 (en) * 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CN107428815B (en) 2015-03-09 2021-07-09 Cytlimic公司 GPC3-derived peptide, pharmaceutical composition for treating or preventing cancer using the same, immunity-inducing agent, and method for producing antigen-presenting cells
AU2016244570B2 (en) * 2015-04-07 2020-08-27 Nec Corporation Medicine
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Preparations and methods for the treatment of cancer
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (en) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN108204958A (en) * 2016-12-19 2018-06-26 伊缪泰普有限公司 binding assay
MA52363A (en) 2018-04-26 2021-03-03 Agenus Inc THERMAL SHOCK PROTEIN (HSP) PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE
SG11202102827YA (en) * 2018-09-27 2021-04-29 Genocea Biosciences Inc Treatment methods
JP2020138940A (en) 2019-02-28 2020-09-03 テルモ株式会社 Therapeutic method

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002922A1 (en) * 1987-10-02 1989-04-06 Genentech, Inc. Adheson variants
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
EP0385909A2 (en) * 1989-03-03 1990-09-05 MicroGeneSys, Inc. A kit or composition for the prevention or treatment of HIV-1 infections
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
WO1991010682A1 (en) * 1990-01-08 1991-07-25 Institut National De La Sante Et De La Recherche Medicale Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
WO1995021528A1 (en) * 1994-02-14 1995-08-17 The General Hospital Corporation Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells
WO1995030750A2 (en) * 1994-05-06 1995-11-16 Institut Gustave Roussy Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
WO1996004386A1 (en) * 1994-08-05 1996-02-15 Warner-Lambert Company Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity
WO1996020215A2 (en) * 1994-12-23 1996-07-04 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
WO1997024132A1 (en) * 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02231083A (en) * 1988-08-31 1990-09-13 Eisai Co Ltd Recombinant natural killer cell-activating factor
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
SE510135C2 (en) * 1994-05-05 1999-04-19 Berol Nobel Ab Aqueous suspension of a cellulose ether, methods for its preparation and composition

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002922A1 (en) * 1987-10-02 1989-04-06 Genentech, Inc. Adheson variants
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
EP0385909A2 (en) * 1989-03-03 1990-09-05 MicroGeneSys, Inc. A kit or composition for the prevention or treatment of HIV-1 infections
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
WO1991010682A1 (en) * 1990-01-08 1991-07-25 Institut National De La Sante Et De La Recherche Medicale Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
WO1995021528A1 (en) * 1994-02-14 1995-08-17 The General Hospital Corporation Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells
WO1995030750A2 (en) * 1994-05-06 1995-11-16 Institut Gustave Roussy Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
WO1996004386A1 (en) * 1994-08-05 1996-02-15 Warner-Lambert Company Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity
WO1996020215A2 (en) * 1994-12-23 1996-07-04 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
WO1997024132A1 (en) * 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAIXERAS E ET AL: "CHARACTERIZATION OF THE LYMPHOCYTE ACTIVATION GENE 3-ENCODED PROTEIN. A NEW LIGAND FOR HUMAN LEUKOCYTE ANTIGEN CLASS II ANTIGENS", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, August 1992 (1992-08-01), pages 327 - 337, XP000677772 *
DRANOFF ET AL.: "Prospects for the immunotherapy of cancer using genetically modified tumour cells", KLINISCHE PHARMAKOLOGIE, vol. 9, September 1992 (1992-09-01), pages 22 - 29, XP002058638 *
HUARD ET AL.: "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand", IMMUNOGENETICS, vol. 39, 1994, pages 213-217, XP002058640 *
HUARD ET AL.: "T cell major histocompatibility complex class II molecules downregulate CD4+ T cell clone responses following LAG-3 binding", EUR. J. IMMUNOLOG., vol. 26, 1996, pages 1180 - 1186, XP000672293 *
HUARD ET AL.: "T cell MHC class II molecules downregulate T cell proliferation following LAG-3 binding", 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY: SAN FRANCISCO, CALIFORNIA, USA, XP002050654 *
WAHREN B: "Gene vaccines", IMMUNOTECHNOLOGY, vol. 2, no. 2, June 1996 (1996-06-01), pages 77-83, XP004052672 *
WILLIAMS ET AL.: "Genetic infection induces protective in vivo immune responses", DNA AND CELL BIOLOGY, vol. 12, no. 8, 1993, pages 675-683, XP002058639 *

Also Published As

Publication number Publication date
IL134212A (en) 2012-03-29
IL134212A0 (en) 2001-04-30
EA200000161A1 (en) 2000-10-30
EP0893507A1 (en) 1999-01-27
NO20000378L (en) 2000-01-25
JP4723722B2 (en) 2011-07-13
EA200300092A1 (en) 2003-06-26
AU753738B2 (en) 2002-10-24
EA200200565A1 (en) 2002-10-31
EP1698701A1 (en) 2006-09-06
CN1265149A (en) 2000-08-30
CA2293805A1 (en) 1999-02-04
KR20010021706A (en) 2001-03-15
HK1030014A1 (en) 2001-04-20
EP1002108A2 (en) 2000-05-24
AU9254798A (en) 1999-02-16
US20020192195A1 (en) 2002-12-19
DK1002108T3 (en) 2006-08-21
ES2262242T3 (en) 2006-11-16
JP2001510806A (en) 2001-08-07
DE69834330D1 (en) 2006-06-01
KR100603075B1 (en) 2006-07-20
US7109026B2 (en) 2006-09-19
CA2732570A1 (en) 1999-02-04
EE200000039A (en) 2000-10-16
EA005405B1 (en) 2005-02-24
UA75322C2 (en) 2006-04-17
DE69841866D1 (en) 2010-10-07
US6410509B1 (en) 2002-06-25
CA2732570C (en) 2014-11-18
DE69834330T2 (en) 2007-03-29
WO1999004810A2 (en) 1999-02-04
PT1002108E (en) 2006-09-29
EP1698701B1 (en) 2010-08-25
EA003740B1 (en) 2003-08-28
CA2293805C (en) 2011-05-03
BR9811037A (en) 2000-08-01
EP1002108B1 (en) 2006-04-26
NO20000378D0 (en) 2000-01-25
ATE324455T1 (en) 2006-05-15
CN1184320C (en) 2005-01-12
ATE478956T1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
WO1999004810A3 (en) Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
ID21529A (en) METHODS AND COMPOSITIONS FOR TUMOR TREATMENT, PREVENTION, RELATIONSHIP RELATED TO TUMORS AND COCOEX
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
ATE106013T1 (en) GLUCAN AND ADJUVANT DRUG DELIVERY SYSTEM.
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
DE69637571D1 (en) COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
IL126803A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1820514A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
BR0111024A (en) Compositions and methods for breast cancer therapy and diagnosis
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
MY127452A (en) Vaccines.
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
WO1997033620A3 (en) Compounds for treating tumours
BR0212446A (en) Use of 4-pyridylmethylphthalazine for cancer treatment
NZ501641A (en) Ganglioside immunostimulating complexes and their use in treating cancer
WO2003020306A1 (en) Desensitizers
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
DE59712247D1 (en) MAMMA CARCINOMA ASSOCIATED GEN
EP1422238A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
DE50305753D1 (en) METHOD AND AGENT FOR THE PREVENTION, INHIBITION AND THERAPY OF CANCER DISEASES

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134212

Country of ref document: IL

Ref document number: 98807547.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2293805

Country of ref document: CA

Ref document number: 2293805

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/012024

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 92547/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020007000265

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998945090

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09492113

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200000161

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998945090

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007000265

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 92547/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007000265

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998945090

Country of ref document: EP